Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
BJCT.OB > SEC Filings for BJCT.OB > Form 8-K on 14-Jul-2009All Recent SEC Filings

Show all filings for BIOJECT MEDICAL TECHNOLOGIES INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for BIOJECT MEDICAL TECHNOLOGIES INC


14-Jul-2009

Entry into a Material Definitive Agreement, Financial Statements


Item 1.01 Entry into a Material Definitive Agreement

On July 8, 2009, Bioject Medical Technologies Inc. ("Bioject") entered into amendment to its lease agreement, effective June 30, 2009, with MEPT Commerce Park Tualatin II and III LLC (the "Landlord") related to its Tualatin, Oregon facility (the "Partial Abatement III"). The Partial Abatement III provides that rent in the amount of $12,000 for each of May and June 2009 be deferred until a later date as described below. Landlord, in its sole discretion, may, by written notice, extend the period of Partial Abatement III on a month-to-month basis through December 31, 2009. Amounts deferred under Partial Abatement III, plus accrued interest at the rate of 9% per annum, shall be due within sixty
(60) days upon the earlier to occur of (i) sale of all or substantially all of Bioject's assets or the acquisition or merger of Bioject or the occurrence of any other transaction identified in Section 4.15.4 of the original lease agreement, (ii) capital or equity raise of $3.0 million or more, (iii) strategic partnership with up-front payments over $300,000, (iv) default by Bioject under the lease; provided, that if none of the foregoing events have occurred by December 31, 2010, Bioject shall commence paying back amounts deferred under Partial Abatement III (plus interest) in twelve (12) equal installments at the same time and in the same manner as Base Rent commencing on January 1, 2011 and on the first of each month thereafter until paid in full. The parties acknowledge that amounts previously deferred pursuant to prior lease amendments are still accruing. The schedule attached as Exhibit A to Exhibit 10.1 shows the total amount accruing to date and the payment schedule.

On July 13, 2009, Bioject entered into a Convertible Subordinated Promissory Note Second Extension Agreement (the "Second Extensions") with each of Life Sciences Opportunities Fund II (Institutional), L.P. and Life Sciences Opportunities Fund II, L.P. (collectively, the "LOF Funds") relating to those two Convertible Subordinated Promissory Notes, dated as of December 5, 2007, issued by Bioject to the LOF Funds in the aggregate principal amount of $600,000 (the "Notes"). The Second Extensions extend the maturity date of the Notes from July 15, 2009 to August 15, 2009.



Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibits are filed herewith and this list is intended to constitute the exhibit index:

10.1    Fourth Amendment to Lease Agreement between MEPT Commerce Park Tualatin II
        and III LLC and Bioject Medical Technologies Inc. dated June 30, 2009.

10.2    Convertible Subordinated Promissory Note Second Extension Agreement, dated
        July 13, 2009, between Bioject Medical Technologies Inc. and Life Sciences
        Opportunities Fund II (Institutional), L.P.

10.3    Convertible Subordinated Promissory Note Second Extension Agreement, dated
        July 13, 2009, between Bioject Medical Technologies Inc. and Life Sciences
        Opportunities Fund II, L.P.


  Add BJCT.OB to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for BJCT.OB - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.